The main reasons behind variability in detection of prolactin and causes of true or apparent discordance with clinical state;Przyczyny rozbieżności wyników oznaczeń prolaktyny i powody prawdziwej albo pozornej niezgodności ze stanem klinicznym

Endokrynologia Polska

Volumn 59, Issue 1, 2008, Pages 30-32

  Jeske, Wojciech ^a  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Hook effect; Macroprolactinemia; Prolactin

Indexed keywords

PROLACTIN; BIOLOGICAL MARKER; PROLACTIN, POLYMERIC;

ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH STATUS; IMMUNORADIOMETRIC ASSAY; PROLACTIN BLOOD LEVEL; REVIEW; BLOOD; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HYPERPROLACTINEMIA; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERPROLACTINEMIA; PROLACTIN; SENSITIVITY AND SPECIFICITY;

EID: 42249094722     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. St. Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinology 1996; 44: 305-309.
2. Jeske W, Gorzelak K, Snochowska H, Zgliczynski W. Credibility of high prolactin levels measured by immunoradiometric assay. Pol J Endocrinol 1998; 49: 97-103.
3. Frieze T, Mong D, Koops M. "Hook effects" in prolactinomas: case report and review of literature. Endocr Pract 2002; 8: 296-303.
4. Laboeuf R, Langlois M, Martin M, Ahnadi Ch, Fink G. "Hook effect" in calcitonin immunoradiometric assay in patients with metastatic medullary thyroid carcinoma. Case Reports and Review of the Literature. J Clin Endocrinol Metab 2006; 91: 361-364.
5. Hirata Y, Tominaga M, Ito J, Noguchi A. Spontaneous hypoglycaemia with insulin autoimmunity in Graves disease. Annals of Int Medicine 1974; 81: 214-218.
6. Smith T, Suliman A, Fahie-Wilson M, Mc Konna J. Gross variability in the detection of prolactin in sera containing big big prolactin (marcoprolacHn) by commercial immunoassays. J Clin Endocrinol Metab 2002; 87: 5410-5415.
7. Jeske W. Makroprolaktyna jako przyczyna bledow diagnostycznych. Endokrynol Pol 2003; 54: 574.
8. Hattori N, Ikekubo K, Ishihara T, Moridera K, Hino M, Kurahachi H. Correlation of antibody titers with serum prolactin levels and their clinical course in patients with anti-prolactin autoantibody. Europ J Endocrinol 1994; 130: 438.
9. Jeske W, Zgliczyński W, Gorzelak K. Makroprolaktyna u osób z hiperprolaktynemia̧. Obserwacje kliniczne i relacje pomiȩdzy frakcja̧ prolaktyny wolnej i frakcja̧ prolaktyny zwia̧zanej z IgG. Endokrynol Pol 2005; 56: 780-784.
10. Hattori N, Ikekubo K, Ishihara T, Moridera K, Hino M, Kurahachi H. A normal ovulatory women with hyperprolactinemia: presence of anti-prolactin autoantibody and the regulation of prolactin secretion. Acta Endocrinol 1992; 126: 497-500.
11. Vallette-Kasic S, Morange-Ramos I, Selim A i wsp. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocr Metab 2002; 87: 581-588.
12. Strachan M, Teoh W, Don-Wauchope A, Seth J, Stoddart H, Beckett G. Clinical and radiological features of patients with macroprolactinaemia. Clin Endocrinol 2003; 59: 339-346.
13. Gibney J, Smith T, Mc Kenna J. Clinical relevance of macroprolactin. Clin Endocrinol 2005; 62: 633-643.
14. Jeske W, Zgliczyński W, Zdunowski P. Laboratory and clinical experience in 55 patients with macroprolactinaemia identified by a simple polyethylene glycol precipitation method (letter to editor). J Clin Endocrinol Metab 2002; 87: 1909-1910.